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The use of systemic corticosteroids, together with bronchodilators and oxygen therapy, has
become established for the management of acute asthma. These agents are undoubtedly
effective, but are also associated with problems such as metabolic adverse effects. Inhaled
corticosteroids (ICS) offer potential benefit in the acute setting because they are delivered
directly to the airways. They are also likely to reduce systemic exposure, which would lead
in turn to reductions in rates of unwanted systemic effects. In order to evaluate the role of
budesonide in the management of acute asthma exacerbations we conducted a review of
the literature and critically evaluated the rationale for the use of ICS in general in this
setting.
Trials in adults and children requiring treatment for acute exacerbation of asthma have
shown clinical and/or spirometric benefit for budesonide when delivered via nebulizer, dry
powder inhaler, or aerosol in the emergency department, hospital and follow-up settings.
The efficacy seems to benefit from high doses given repeatedly during the initial phase of
an acute exacerbation. These acute effects are likely to be linked to the drug’s distinctive
pharmacokinetic and pharmacodynamic profile. The current evidence base revealed
encouraging results regarding the efficacy of the ICS budesonide in patients with wheeze
and acute worsening of asthma. Future studies should focus on the efficacy of these agents
in more severe asthma worsenings.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
41 6767.
.com.
ARTICLE IN PRESS
B. Volovitz686Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 686
Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 686
Adverse effects of short courses of systemic corticosteroids provide a rationale for the use of ICSs. . . . . . . . . . 687
ICSs may give a faster effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 687
ICSs in wheeze . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 687
ICSs in acute worsenings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 687
ICSs in acute asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 688
Doses and dosing schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 688
The importance of high doses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 689
Clinical experience with budesonide in acute asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 689
Budesonide in acute asthma in adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 689
Budesonide in acute asthma in children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 690
In the emergency department. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 690Comparisons with placebo: single dose administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 690
Repeated dosing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 691
Comparison to systemic steroids: single dose administration . . . . . . . . . . . . . . . . . . . . . . . . . 692
Comparison to systemic steroids: repeated dosing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692
Inhaled budesonide in addition to systemic steroids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692Hospitalized patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692
Differences between ICS in the acute setting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692
Dissolution and lipophilicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692
Rapid onset of action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 693
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 693
Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 694
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 694Introduction
Asthma is a chronic inflammatory disease, characterized by
reversible airway obstruction in response to various stimuli.
Exacerbations, manifesting as the temporary worsening of
symptoms, form part of the natural history of the disease,
but may also represent failure of ongoing long-term therapy.
They also commonly lead to emergency department
presentation and hospitalization, and to complications in
the longer term.1
Acute asthma exacerbations often present differently in
children and adults. According to British guidelines, acute
exacerbation of asthma in adults ranges from brittle
asthma, or wide variation in peak expiratory flow rates
(PEFRs) and sudden severe attacks against a background of
apparently well controlled disease, to near fatal asthma
where mechanical ventilation is necessary.2
Acute severe asthma in adults is characterized by reduced
PEFR, raised respiratory and heart rates, and an inability to
complete spoken sentences in one breath. In children, the
definition of acute disease is much simpler, with acute
severe asthma being described as an inability to complete
sentences in one breath or being too breathless to
talk or feed, with raised respiratory and heart rates.2
The US National Institutes of Health (NIH) recommendations
state simply that asthma exacerbations are acute or
subacute episodes of progressively worsening shortness of
breath, wheezing, and chest tightness or some combination
of these symptoms, and that early treatment is the
best management strategy.3 This has been seen in studies
such as that of Volovitz et al.,4 in which an inhaledcorticosteroid (ICS) was used for acute asthma in children
in the home setting.
British and US guidelines address the issue of acute
asthma exacerbation by recommending as the main ther-
apeutic interventions oxygen, inhaled b2-agonists and
systemic corticosteroids.2,3 The central role of systemic
corticosteroid treatment is underlined by the observation
from the literature that treatment within an hour of
presentation reduces the need for subsequent hospitaliza-
tion, with greatest benefit being seen in patients with
severe exacerbations.1 Moreover, the significant spirometric
improvements seen after corticosteroid therapy are main-
tained for up to 3 days.5 Despite its undoubted effective-
ness, there are problems with the treatment approach
currently recommended. Debate remains over which do-
sages of the systemic corticosteroids available should be
used.6 Questions relating to the optimum balance between
corticosteroids and b2-agonists also remain to be answered
definitively,7 with British and American guidelines differing
on this point.2,3
In this review, we critically evaluate the rationale for the
use of ICS in the management of acute asthma exacerbations
and evaluate the role of budesonide in the management of
such exacerbations in both adults and children.
Methods
Two Cochrane systematic reviews formed the basis for data
collection, one of the early use of ICSs in the emergency
department treatment of acute asthma8 and one of inhaled
steroids for episodic viral wheeze of childhood.9 Additional
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search terms that included: budesonide, ICS, asthma
exacerbations, asthma worsenings, acute asthma, systemic
corticosteroids, wheeze, and children.
Adverse effects of short courses of systemic
corticosteroids provide a rationale for the use
of ICSs
Short courses of systemic corticosteroid therapy for acute
asthma exacerbations are undoubtedly effective in provid-
ing lasting symptomatic relief, are relatively inexpensive
and are associated with good compliance.5 However, the
adverse effects of long-term systemic corticosteroid therapy
are well documented10 and concerns persist over the long-
term safety of repeated short courses of systemic corticos-
teroid therapy. Such concerns warrant clinical evaluation
and require clinicians to undertake a risk:benefit assessment
when considering systemic corticosteroid therapy given the
availability of effective alternative treatment choices—ICS.
Adverse effects associated with systemic corticosteroid
therapy including bone loss, may be less pronounced with
ICS, perhaps as a result of their delivery directly to the
desired site of action.11
Serum osteocalcin measurements in patients receiving
corticosteroids have indicated that even short, intermittent
courses of systemic agents have undesirable effects on bone
metabolism in patients with asthma, and that the use of
inhaled rather than systemic corticosteroids reduces this
risk substantially.12
A direct comparison between nebulized budesonide
(Pulmicorts Respuless), which has been used in many
studies of inhaled steroids in acute asthma, and oral
prednisolone shows a clear benefit for the former. Wilson
et al.13 compared the systemic activity of budesonide 1, 2
and 4mg with oral prednisolone 5, 10, and 20mg over 4 days
in patients with mild asthma. For morning plasma cortisol,
serum osteocalcin, and blood eosinophils, there was a
significant dose-related suppression with prednisolone but
not with budesonide.1
In acute settings the apparent difference between
inhaled and systemic corticosteroids has also been docu-
mented in school children14,15 as well as in infants16 using
markers of bone turnover and HPA-axis measurements. A
dose-related effect on osteocalcin was seen for oral
prednisolone 2.5 and 5mg but not for inhaled budesonide
200 and 800 mg (pMDI and spacer) among prepubertal school
children.15 In smaller children (1–3 years), 10 days of
inhaled budesonide (400 mg qid for 3 days and 400 mg bid
for 7 days) did not influence serum or urinary cortisol or
markers of bone turnover.16
Dolan et al.17 investigated the adrenal dynamics through
hypoglycemia and ACTH stimulation in asthmatic children
11–15 years old who during the previous year had received
repeated ‘‘bursts’’ (less than 7 days) of short-term high-dose
prednisone (1–2mg/kg/day) for acute exacerbations. Most
children had a normal adrenal response, however in those
who received more than 4 ‘‘bursts’’ per year a subnormal
response was seen.
There have also been concerns with respect to the acute
psychiatric effects of systemic steroids.18ICSs may give a faster effect
There is evidence that the inhaled route may provide an
even faster onset of effect than systemic steroids. This
apparent benefit has been documented in acute severe
asthma in adults19,20 and in children with moderately severe
acute asthma.21 There may also be a benefit for ICS with the
concomitant use of inhaled beta-agonists. One study has
suggested that ICS might enhance b2-agonist responsive-
ness.22 ICS have thus attracted attention as a potential
alternative to systemic therapy in acute asthma.
ICSs in wheeze
An evidence-based and comprehensive review of the
literature in children concluded that episodic treatment
with a high dose of ICS is beneficial in children with mild,
virally induced wheezing, whereas maintenance treatment
with a low dose provides no benefit.9 Five randomized
controlled trials in children with mild viral episodic wheeze
were identified by the reviewers: there were significant
overall reductions in oral corticosteroid requirements in two
double-blind crossover studies in which high doses of ICS
were used, and a significant preference by parents for the
active treatment over placebo. More recent studies further
support the utility of ICS in the management of childhood
wheeze.23,24
There are also more specific data to show efficacy of
inhaled budesonide in children with wheezing induced by
respiratory infections. Three double-blind studies have
shown beneficial effects of budesonide in children aged
from 1 to 10 years (Table 1). Connett and Lenney25 showed a
preference for budesonide over placebo in addition to
reductions in day- and night-time wheezing. Svedmyr et
al.26 demonstrated notable reductions in acute healthcare
resource consumption in terms of emergency room atten-
dance and hospital admissions with budesonide in one study
in which Turbuhalers was used in children aged 3–10 years.
The need for hospital care was not reduced by budesonide in
another study by these authors that involved very young
children (1–3 years), but reductions in symptom scores
(cough, wheeze, noisy breathing, and breathlessness) as
recorded by parents were reported.27
ICSs in acute worsenings
An Italian group28 investigated the use of short-term
increases in budesonide Turbuhalers dosage to control
asthma worsening in patients already receiving maintenance
treatment with budesonide 100 mg twice daily. In 67 patients
with moderate asthma receiving long-term therapy with
budesonide 100 mg twice daily, budesonide 800 mg daily (to
give a total daily dose of 1000 mg) or placebo was added to
treatment for 7 days at the first sign of an asthma
exacerbation (defined as a 30% fall in PEFR on 2 consecutive
days); placebo inhalers were added for asthma worsening in
the other two groups of patients in this trial (67 receiving
budesonide 400 mg twice daily routinely and 75 receiving
budesonide 100 mg twice daily). Both dosages of budesonide
(800 and 200 mg/day) were effective in controlling symptoms
and maintaining lung function over a period of several
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Table 1 Studies of inhaled budesonide in children with acute wheezing.
Study Patients enrolled Design Treatments Results
Connett and
Lenney25
32 preschoolers
with viral wheezing
R, DB, PC BUD 800 mg bid via spacer or
1600 mg bid via
spacer+mask 7d. Treatment
continued until one pair of
active and PL inhalers used
per patient
28 treatment pairs completed
by 25 patients. 12 families
preferred BUD; 6 PL; 7 no
preference. Mean day and
night time wheeze
significantly reduced by BUD
Svedmyr et al.26 31 aged 3–10 y with
URTI
R, DB, PC, CO BUD TH 0.2mg qid 3d, then
tid 3d, then bid 3d. 2 BUD
and 2 PL courses given per
patient
22 children completed 67
periods. Emergency room
visits: 3 BUD, 8 PL. All
hospital admissions
associated with PL. Morning
and evening PEFR higher with
BUD (P ¼ 0.015; P ¼ 0.022),
but symptom scores similar
for BUD and PL
Svedmyr et al.27 55 aged 1–3 y with
airway infection
R, DB, PC, PG BUD 400 mg or PL qid 3d,
then bid 7d via
spacer+mask. Each child
followed for 1 yr
BUD reduced symptom scores
(especially cough) but not
need for hospital care
Abbreviations: bid ¼ twice daily; BUD ¼ budesonide; CO ¼ crossover; DB ¼ double-blind; PC ¼ placebo-controlled; PEFR ¼ peak
expiratory flow rate; PG ¼ parallel groups; PL ¼ placebo; qid ¼ four times daily; R ¼ randomized; TH ¼ Turbuhaler; tid ¼ three times
daily; URTI ¼ upper respiratory tract infection.
B. Volovitz688months, and that the addition of budesonide 800 mg daily at
the onset of worsening was beneficial.
Volovitz et al.4 investigated the efficacy of high dosages
of budesonide in children aged 1–14 years with acute asthma
exacerbations treated at home. Children received budeso-
nide 200–400 mg four times daily in combination with a b2-
agonist at the first sign of an asthma exacerbation, and the
budesonide dosage was decreased over 4–8 days. Overall,
the children’s parents were able to control 94% of the 1061
asthma exacerbations; in addition, high-dosage budesonide
was associated with a reduced need for oral corticosteroid
therapy and hospitalization.ICSs in acute asthma
In view of the problems (most notably metabolic) with
systemic corticosteroids, and the encouraging findings in
patients with acute wheeze or worsening of asthma, the use
of ICS formulations in patients with acute asthma has been
investigated in a number of studies in the emergency
department and hospital settings as well as following
discharge from the emergency department. This has allowed
a systematic review of the data.8
Edmonds et al.8 investigated early use of ICS in the
emergency department treatment of acute asthma and
compared inhaled steroids vs. placebo and inhaled steroids
vs. systemic steroids in 11 studies. The primary analysis
compared inhaled steroids vs. placebo on hospitalization (5
studies), pulmonary function (4 adult studies) and clinical
scores (2 studies in children). Five of these 7 studies
compared inhaled steroids vs. placebo alone and 2 studiescompared inhaled steroids plus systemic steroids vs.
systemic steroids alone. A total of 191 patients received
treatment with an ICS and 185 did not. The patients who
were given ICS were less likely overall to be admitted to
hospital (odds ratio [OR] 0.30; 95% confidence interval [CI]
0.16–0.57). Patients receiving concomitant systemic ster-
oids showed a similar, but non-significant, trend towards
reduced admissions compared with placebo (OR 0.45; 95%
CI: 0.18–1.12). Patients who received ICS also showed small
but nevertheless significant improvements in PEFR (8%;
95%CI: 3–13%) and FEV1 (5%; 95%CI: 0.4–10%). The secondary
analysis compared ICS alone with systemic treatment alone.
Four such studies were identified and all involved pediatric
patients. Of a total of 313 patients, 159 received inhaled
steroids, and 154 systemic steroids. There was a marked
heterogeneity between study results and meaningful pooling
of results was not possible.8Doses and dosing schedules
In the studies included by Edmonds et al.8 there was a wide
variety in doses and dosing schedules. Three of the studies
included in the primary analysis gave a single dose of ICS
(beclomethasone;29 budesonide30,31), while the others gave
multiple doses (from 3 doses [budesonide32] to 18 doses
[flunisolide19]) over 3–8 h. Total doses ranged from low
(beclomethasone 200 mg)29 to very high (flunisolide 18mg).19
In the analysis of ICS vs. oral steroid, three studies gave a
single dose of ICS,14,21,33 and one gave three doses.34 The
doses of ICS were moderate to high (budesonide 1600 mg and
dexamethasone 1.5mg/kg).14,21 All four used 2mg/kg of
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group.
It is notable that all studies in the primary analysis which
used budesonide showed a favorable outcome31,32 and this
was also the case in the study by Sung et al.,30 where
budesonide was added to systemic steroids.
In the comparisons between ICS and systemic steroids in
children the two studies with budesonide14,34 showed better
or equal efficacy. The study by Scarfone et al.21 showed
equal efficacy between inhaled dexamethasone and
prednisone. The only study comparing fluticasone with a
systemic steroid (prednisone) showed better outcomes
(including improvements in the forced expiratory volume
over 1min [FEV1] and the requirement for subsequent
hospitalization) when patients received systemic steroid
therapy.33 The authors recommended that inhaled flutica-
sone should not be used to treat severe acute asthma.The importance of high doses
Our understanding of the dose–effect relationship of inhaled
steroids in acute and severe asthma has increased in recent
years. Experience with patients who deteriorate during
maintenance treatment have shown that, on the whole, a
simple doubling of the usual maintenance ICS dose is
unlikely to be sufficient in the acute setting.35 In a study
among 28 children with mild to moderate asthma failed to
demonstrate a benefit for increasing ICS dose compared with
placebo for morning or evening PEFRs, diurnal peak flow
variability, symptom scores, spirometric function or the
parents opinion of the effectiveness of asthma medica-
tion.35 Most studies showing a beneficial effect of ICS during
acute asthma attacks used doses at least five times those
usually given by inhalation for maintenance ther-
apy.14,19,30,32,34,36,37 In the systematic review by Edmonds
et al.8 six randomized, double-blind and controlled studies
compared treatment with oral corticosteroids with ICS; the
high doses used in these studies included budesonide 2400 mg
via nebulizer as three doses of 800 mg at 30-min intervals,34
budesonide 2000 mg via nebulizer every 8 h,37 budesonide
1600 mg via DPI,14 dexamethasone 1.5mg/kg via nebulizer,21
budesonide via MDI with spacer as three 400 mg doses at 30-
min intervals,32 and fluticasone 1000 mg via nebulizer twice
daily.36 ICS were generally at least as effective as oral
corticosteroids in controlling acute asthma attacks in the
emergency setting; in only one study did ICS not prove to be
as effective as the oral comparator in terms of all
parameters measured.35
The high doses and the high frequency of administration
may be requisites to provide both a rapid and an additive
effect of inhaled steroids on top of a regimen already
including systemic steroids. Such an approach would be
especially valuable in acute severe asthma.38 The high dose
effects may involve non-genomic effect of inhaled steroids
as recently suggested by Horvath and Wanner39 and Rhen
and Cidlowsky.40 These effects may be more rapid than
those corticosteroid effects than involve genomic transcrip-
tion, but may be more transient as has been noticed for the
acute vasoconstrictor effect studied by Mendes et al.,41
which only lasted 2 h in spite of high doses of ICS. Clinical
benefits may comprise effects on mucosal edema through adirect effect on mucosal blood vessels,41 but may also
comprise acute effects on plasma exudation and bronchial
secretion as suggested by Urbach et al.42 The relevance of
these observations needs further study.
Clinical experience with budesonide in acute
asthma
The efficacy of budesonide in the acute setting has been
investigated in adults and in children in emergency depart-
ments, in hospitalized patients, and during the follow-up
period after discharge.
Budesonide in acute asthma in adults
Two studies43,44 have compared nebulized budesonide given
in repeated high doses with oral steroids in adults with
severe acute asthma undergoing treatment in the emer-
gency department (Table 2). Both studies showed no
relevant difference between nebulized budesonide and oral
prednisolone in terms of improvement in FEV1. However,
nebulized budesonide significantly reduced severity of
wheezing relative to prednisolone at 24 and 48 h.43 During
the follow-up phase, FEV1 was significantly higher in the
budesonide group than in the prednisolone group after 28
days, and coughing was reduced after 7 days. It should be
noted that this study was incomplete because of difficulties
with recruitment, and the trial did not have sufficient power
to detect a difference between treatments in terms of FEV1.
Mitchell et al.44 reported similar spirometric improvements
after 24 h in patients treated with nebulized budesonide
(five doses of 4mg) and in those who received high- and low-
dose oral prednisolone (four oral doses of 40mg or a single
30mg dose).
Inhaled budesonide has also been investigated in patients
discharged from hospital after an acute attack of asth-
ma43,45–47 (Table 2). Two of these randomized double-blind
studies45,46 showed similar efficacy of systemic treatment
and inhaled budesonide via Turbuhalers. Fitzgerald et al.45
studied 185 patients and found budesonide 600 mg four times
daily for 7–10 days was as effective as prednisone 40mg
daily in terms of relapse rates, quality of life, symptoms,
and spirometry (Table 2). High-dosage budesonide via DPI
was recommended by the authors as a viable alternative to
systemic prednisone as follow-up treatment in patients with
acute asthma stabilized in the emergency department.
Nana et al.46 reached similar conclusions in their study in
81 patients. These researchers used a higher dosage of
budesonide (1600 mg twice daily) and compared this with a
tapering course of prednisolone (Table 2). Increases in
spirometry were similar between groups (Fig. 1), as were
clinical improvement, and need for rescue medication.
In a further study, inhaled budesonide was added to a 21-
day course of oral prednisolone after initial stabilization in
the emergency department.47 This trial showed a halving of
relapse rates over 21 days of follow-up and reduced b2-
agonist usage when budesonide 1600 mg daily via Turbuha-
lers was added to nontapering oral prednisone 50mg/day
for 7 days (Table 2). Addition of budesonide also resulted in
better asthma quality of life (AQLQ) scores. Pulmonary
function was similar between groups, and b2-agonist
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Table 2 Studies of inhaled budesonide in adult patients with acute asthma.
Study Patients Design Treatments Results
Hospitalized patients
Higenbottam et al.43 13 R BUD neb 4mg q8h 48–72 h; then
BUD TH 1600 mg bid 7 d; then BUD
TH 800 mg bid 2 d
Similar increases in FEV1 between
groups after 48 h; coughing reduced
in BUD group after 7 days; FEV1
higher in BUD group after 28 d
PRED 40mg/d 9–11 d; then BUD
TH 800 mg bid 21 d
Mitchell et al.44 135 R BUD neb 4mg 5 doses over 18 h Similar increases in PEFR in all
groupsPRED 40mg 4 doses over 18 h
PRED 30mg stat
Follow-up after discharge from the emergency department
Fitzgerald et al.45 185 R, DB BUD TH 600 mg qid 7–10 d Relapse rates 10% (BUD) and 11.8%
(PRED); similar improvements
between groups in FEV1, symptoms,
PEFR and QoL scores
PRED 40mg/d 7–10 d
Nana et al.46 81 R, DB BUD TH 1600 mg bid 7d Similar increases in FEV1 and mean
morning PEFR; also symptoms and
use of rescue medication
PRED 40mg, reducing to 5mg over
7 d
Rowe et al.47 188 R, DB BUD 1600 mg/d+PRED 50mg 21 d Relapse rates: 12.8% (BUD) and
24.5% (PL); AQLQ scores higher and
fewer b2-agonist actuations with
BUD
PL+PRED 50mg 21 d
Abbreviations: AQLQ ¼ Asthma Quality-of-Life Questionnaire; BUD ¼ budesonide; DB ¼ double-blind; FEV1 ¼ forced expiratory
volume in 1 s; neb ¼ nebulized; PEFR ¼ peak expiratory flow rate; PL ¼ placebo; PRED ¼ oral prednisolone/prednisone; QoL ¼ quality
of life; R ¼ randomized; TH ¼ Turbuhaler.
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Figure 1 Mean changes in percentage predicted forced
expiratory volume in 1 s (FEV1) and peak expiratory flow (PEFR)
from baseline to 7 days after emergency room treatment for an
acute asthma attack with either budesonide 1600 mg twice daily
via dry powder inhaler for 7 days or oral prednisolone tapering
from 40 to 5mg daily over 7 days.46Budesonide in acute asthma in children
Most studies in children have been performed in the
emergency department setting,14,30,32,34,48 but some data
are also relevant to those who are ultimately hospita-
lized37,49 and to those being followed up.14,37 It should be
noted that all pediatric studies to date show comparable
efficacy for inhaled budesonide and oral corticosteroids in
the control of acute asthma exacerbations. A feature of the
results of studies in children has been the apparent
potential for reduced consumption of healthcare resources
as shown by reduced hospitalization times or accelerated
discharge from hospital in patients treated with inhaled
budesonide.30,32,34,48
An early study by Djaugberg et al.49 showed benefit of
addition of nebulized budesonide to systemic corticosteroid
or inhaled terbutaline. Budesonide 0.5mg was inhaled every
4 h for up to 5 days and was associated with significantly
improved symptom scores relative to placebo in children
with acute wheezing. Subsequent randomized and double-
blind studies have shown at least as much clinical benefit
with inhaled budesonide as with oral prednisolone/predni-
sone across a wide range of ages (Table 3).In the emergency department
Comparisons with placebo: single dose administration
A double-blind study by Tsai et al.31 in children aged 6–17
years found acute treatment with budesonide inhalation
suspension (up to 2mg effective). A single dose of nebulized
budesonide, but not nebulized terbutaline, rapidly de-
creased exhaled NO levels in 6 h. The decrease in exhaled
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Table 3 Studies of inhaled budesonide in infants and children with acute asthma.
Study Patients (age
range)
Design Treatments Results
Emergency department
Singhi et al.32 60 (3–12 yr) R, DB O2+SAL neb+BUD pMDI
q30min 3
Hospitalization rates: BUD ¼ 0%;
PL ¼ 23%. BUD also reduced O2,
aminophylline and systemic steroid
requirements; improved PEFR and
respiratory distress scores (Po0.05);
reduced length of hospital stay
O2+SAL neb+PL q30
min 3
Devidayal et al.34 80 (2–12 yr) R, DB SAL neb 0.15mg/kg+PL
neb q30min 3+2mg/kg
PRED stat
Fit for discharge after 3 doses: BUD
54%, PRED 18% (Po0.001). O2
saturation, pulmonary index and
respiratory distress scores all
significantly better with BUD
(Po0.01)
SAL neb+BUD neb 800 mg
q30min 3+oral PL
Volovitz et al.14 22 (6–16 yr) R, DB BUD TH 1600 mg, then
reducing doses after
discharge 1wk
Treatments equivalent. During 4 h
treatment both groups showed a
similar improvement in: pulmonary
index score including: oxygen
saturation, respiratory rate,
inspiratory expiratory ratio,
accessory muscle use and wheezing;
earlier response with BUD
PRED 2mg/kg, then
reducing doses after
discharge 1wk
Sung et al.30 44 (6mo–18 yr) R, DB PRED 1mg/kg+SAL neb
0.15mg/kg q30min 3,
then q4 h 4+BUD neb
2mg
Pulmonary index scores similar
between groups (BUD vs PL). Patients
discharged more rapidly from hospital
overall after BUD treatment
PRED 1mg/kg+SAL neb
0.15mg/kg q30min 3,
then q4 h 4+PL neb
Hospitalized children
Sano et al.48 71 (3–24mo) NS BUD neb 0.25mg q6 h+IV
fluids, hydrocortisone
and formoterol neb
Significant reduction in clinical scores
in both groups. Faster improvement
with BUD, and hospitalization
duration reduced (66.4 vs 93 h;
Po0.01)Ipratropium 0.1mg
q6 h+IV fluids,
hydrocortisone and
formoterol neb
Matthews et al.37 46 (5–16 yr) R, DB BUD neb 2mg/kg
immediately and after
24 h
Significant increase in FEV1 (Po0.01
vs baseline) with BUD only. PEFR and
symptoms similar between
treatments (also after 24 d follow-up
with BUD TH 800 mg/d)
PRED 2mg/kg
immediately and after
24 h
Abbreviations: BUD ¼ budesonide; DB ¼ double-blind; FEV1 ¼ forced expiratory volume in 1 s; neb ¼ nebulized; NS ¼ not state-
d;O2 ¼ humidified oxygen; PEFR ¼ peak expiratory flow rate; PL ¼ placebo; pMDI ¼ pressurized metered-dose inhaler; PRED ¼ oral
prednisolone/prednisone; R ¼ randomized; SAL ¼ salbutamol; TH ¼ Turbuhaler.
Inhaled budesonide in acute asthma 691NO, a marker of inflammation, was correlated to an increase
in PEFR.
Repeated dosing
Singhi et al.32 showed elimination of the need for
hospitalization when budesonide via pMDI and spacer was
added to humidified oxygen and bronchodilator therapy(Table 3). Both groups showed significant improvements in
respiratory status after 2 h, but budesonide was associated
with considerable reductions in the proportion of children
needing oxygen for more than 2 h (23% vs. 50%; Po0.05) and
requirement for aminophylline infusion and systemic corti-
costeroid therapy (7% vs. 27%; Po0.05). The mean length of
stay at the emergency department was more than halved by
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Figure 2 Mean areas under curves of plasma drug concentra-
tion vs. time (AUC) for single inhaled doses of budesonide
(800 mg) and fluticasone (1000 mg) before and after challenge
with methacholine.52 The relative reduction in AUC caused by
methacholine challenge was significantly greater for fluticasone
than for budesonide (P ¼ 0.003).
B. Volovitz692the addition of budesonide to acute therapy (from 7.8 to
3.2 h; Po0.01).
Comparison to systemic steroids: single dose
administration
Acceleration of recovery with the use of inhaled budesonide
was demonstrated by Volovitz et al.14 in their study in 22
older children (aged 6–16 years) who presented to the
emergency department with moderately severe asthma
attacks (Table 3). The children were either given a single
dose of budesonide 1600 mg via DPI or 2mg/kg prednisolone,
followed by a tapering algorithm. Tapering budesonide
conferred similar responses in terms of spirometry, pulmon-
ary indices, wheezing, accessory muscle use, and oxygen
saturation to those seen with tapering oral corticosteroid
therapy (see also later discussion of onset of action). Asthma
symptom scores improved more quickly with budesonide
than with prednisolone during the first week after discharge,
and budesonide treatment was not associated with the
cortisol suppression seen at Week 3 in children who had
received prednisolone.
Milani et al.50 found that a single nebulized dose of
budesonide provided comparable clinical improvement to a
single oral dose of prednisone in children (aged 2–7 years)
presenting with mild to moderate exacerbation of their
asthma.
Comparison to systemic steroids: repeated dosing
Devidayal et al.,34 in their study in 80 children aged 2–12
years, found that the rate of full recovery and subsequent
discharge from the emergency department was increased
threefold when a single oral dose of prednisolone 2mg/kg
was replaced with three doses of budesonide 800 mg given at
30-min intervals via nebulizer.
Inhaled budesonide in addition to systemic steroids
Sung et al.30 failed to show benefit of addition of a single
dose of nebulized budesonide to corticosteroid and broncho-
dilator therapy in terms of pulmonary index scores, but did
note a nonsignificant tendency towards a lower median
score (i.e. fewer/less severe symptoms) after 1 h in the
budesonide group than with placebo (P ¼ 0.07).
Hospitalized patients
Sano et al.48 used a pulmonary score that included wheezing
and costal retraction, together with measurements of
respiratory rate, and found significant improvements after
12 h when either nebulized budesonide or ipratropium was
added to standard therapy with a bronchodilator, systemic
corticosteroid and iv fluids, but with more rapid improve-
ment with budesonide (Table 3). Of additional interest are
the observations by Matthews et al.37 in 46 hospitalized
children aged 5–16 years with severe asthma exacerbations.
After 24 h, although nebulized budesonide and oral pre-
dnisolone produced similar improvements in PEFR and
symptoms, only patients treated with budesonide showed
a significant mean change in FEV1 from baseline. Oral
corticosteroid treatment had no significant effect in this
respect.Differences between ICS in the acute setting
Budesonide seems to have a more consistent documentation
in acute settings than steroids such as beclomethasone
dipropionate (BDP) and fluticasone. There may be a
difference on the pharmacokinetic level for these drugs
that help explain these differences.Dissolution and lipophilicity
Budesonide is readily dissolved in human bronchial secre-
tions and is rapidly absorbed irrespective of the site of
deposition, which contrasts with the dissolution profile of
more lipophilic compounds, such as fluticasone.51 This
difference between corticosteroids becomes increasingly
important in patients with pulmonary obstruction where
there is greater central deposition of inhaled drugs and a
faster clearance of lipophilic steroids.
Mortimer et al.52 have shown that, in contrast to
budesonide, the airway availability of fluticasone is severely
restricted by methacholine challenge designed to decrease
FEV1 by over 25%. These authors measured AUCs for the two
corticosteroids after single inhaled doses of fluticasone
1000 mg and budesonide 800 mg with and without the
presence of methacholine. As shown in Fig. 2, the reduction
in mean AUC of fluticasone after methacholine challenge
was considerably greater (60%) than that seen with
budesonide (21%).
An indication that such differences will have clinical
importance in obstructed patients is the finding of a higher
potency of budesonide vs. fluticasone and BDP in the study
by Mendes et al.,41 who studied the acute vasoconstrictor
effects of these three ICS in healthy volunteers and
asthmatic patients (Fig. 3).
Except for considerably lower airway availability of
lipophilic steroids in acute obstructed patients, the rate of
pulmonary absorption of budesonide appears to be an
important factor determining the efficacy of the drug in
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Inhaled budesonide in acute asthma 693the acute setting. Budesonide has a mean absorption time of
0.8 h compared with, for example, the 5.9 h required by
fluticasone.53–56
There is evidence to suggest that lipophilic inhaled
steroids may be less than optimal for the treatment of
acute airway obstruction.33,57,58 Although there are no
published head-to-head comparisons between budesonide
and fluticasone in acute asthma, these two drugs have been
used in our clinic.0
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Figure 4 Time course of effect of inhaled budesonide (1600 mg
via dry powder inhaler) and oral prednisolone (2mg/kg) in
children treated for acute asthma in the emergency department
setting.14Rapid onset of action
Systemic corticosteroids (oral or parenteral) have been
found to be effective in controlling acute asthma attacks
within 4 h in adults59 and children.60,61 Two studies62,63
failed to show a benefit for early administration of IV
corticosteroid in acute asthma, although the balance of
subsequent pooled evidence favored corticosteroid use.59
For budesonide specifically, improvements in lung func-
tion may be apparent as early as 1–4 h after inhalation in
patients with acute or stable asthma14,64 and be accom-
panied by improvements in inflammatory markers after
approximately 4–6 h.65,66 Significant improvements in lung
function were observed with ascending doses of budesonide
(200, 800 and 1600 mg) within 4–5 h, with the highest dose
producing a significant improvement in inflammatory marker
status that was seen from the first day of treatment.66
Vathenen et al.65 showed that budesonide 800 mg twice daily
increased FEV1 and histamine reactivity from the first dose
of budesonide, with maximal changes seen 6 h after
inhalation. In a study of 41 adults with stable asthma who
stopped ICS therapy for 4 days and then received a single
dose either of budesonide 2400 mg or placebo via DPI,
sputum eosinophil levels were significantly lower 6 h after
budesonide (25%) than placebo (37%; Po0.05), and airway
responsiveness improved with budesonide by a factor of
2.2.67 In a study in children,14 clinical activity of both
inhaled budesonide (1600 mg via DPI) and oral prednisolone
(2mg/kg) was noted immediately after administration with
similar effects over the first 4 h of treatment (Fig. 4). At 4 h,
PEFR had improved (Po0.01) to the same extent in both
groups, as had pulmonary index scores (Po0.001), wheezing(Po0.05), accessory muscle use (Po0.001), and oxygen
saturation (Po0.05).
A rapid effect of budesonide on late allergic responsive-
ness has also been reported.68 Administration of budesonide
800 mg via DPI 4–6 h after allergen challenge resulted in a
rapid (after 1–2 h; Po0.001 at 2 h) and sustained reduction
in severity of late-onset allergic reactions when compared
with placebo.Conclusions
Data would suggest that inhaled budesonide has a role in the
management of acute asthma exacerbation and pediatri-
cians and primary care physicians are starting to recommend
increases in dosage of ICS at home at the onset of an asthma
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B. Volovitz694exacerbation.69 Studies of inhaled budesonide have shown
consistently positive results, with no indication that such
therapy is inferior to oral corticosteroid therapy. These
findings contrast with those for some other ICS dies of ICS
and making cross study comparisons in the acute exacerba-
tion setting given the difficulty in defining clinically relevant
and measurable severity thresholds for asthma worsenings
and exacerbations.
The apparent efficacy of inhaled budesonide in patients
with acute asthma is most probably linked to the drug’s
pharmacokinetic profile, with key factors including rapid
penetration of target tissues and fast onset of action.
In addition to further work to clarify clinically relevant
severity thresholds of acute asthma exacerbations, further
studies are now warranted in patients with more severe
asthma exacerbations to more fully define the role of
budesonide and other ICS in this setting.
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